eHIV Review

Take our post-test to claim CME credits. To read a companion newsletterclick here. Both the on-goingsyphilis and HIV epidemicsare highly concentrated among men who have sex with men.WhilePrEPhas beenprovento reduce HIV transmission, it is not designed toprevent sexually transmitted infections like gonorrhea, syphilis, and chlamydia. What does the evidence sayabout reducing STI risk in MSM, and how can it be most effectively applied in practice? In this podcast,Dr.Matthew Spinelli—Assistant Professor in the Division ofHIV, ID, and Global Medicineat theUniversity of California, San Francisco and San Francisco General Hospital— takes us to the clinic to explain what providers can do to help their patients avoid acquiring and transmitting STIs.

Take our post-test to claim CME credits. To read a companion newsletterclick here. Our ability to reduceHIVinfection and transmissiondepends on testing, in particular assessing the status of at-riskpeoplewho continue to remain untested. In this issue, Dr. Cedric Bien-Gund from the Division of Infectious Diseases at the University of Pennsylvania takesus to the clinic to explain the pros and cons of the currently available HIV tests and explainswhich are best to use in particular clinical circumstances.

Take our post-test to claim CME credits. To read a companion newsletterclick here. In the US,nearly half of all peopleliving with HIVare now aged50 yearsor older. Theirhealth care providersface new challenges in managing the effects of aging in their patients. In thiseHIVReview podcast,Dr.Maile Young KarrisfromtheUniversity of CaliforniaSan Diegoprovides clinical insight into HIV and aging.

Take our post-test to claim CME credits. To read a companion newsletterclick here. In the US, amongwomen at high risk for acquiring HIV infection, only around 2%have initiatedPrEP. Whatarethe patient, provider, and system barriers to increasedPrEPuptake in this vulnerable population? What can clinicians do to overcome these barriers?In this issue, Dr. Rachel Scott,Scientific Director of Women's Health Research at the MedStar Health Research Institute and Assistant Professor of Obstetrics and Gynecology at the Georgetown University School of Medicine,provides some answers.

Take our post-test to claim CME credits. To read a companion newsletterclick here. People who inject drugs (PWID) are at risk for HIV infection from both sexual- as well as injection-related causes. What can clinicians do to reduce the incidence of infection and improve their patients’ health?In this issue, Dr. Jessica Taylor from The Boston University School of Medicine and Boston Medical Center takes us into the clinic to explain how current evidence-based strategies can increase the uptake of HIV pre-exposure prophylaxis in this vulnerable population.

Take our post-test to claim CME credits.To read a companion newsletter click here.In her recent newsletter issue (eHIV Review V5 #1), Dr. Ethel Weld, Assistant Professor of Medicine, Pharmacology and Molecular Sciences at the Johns Hopkins School of Medicine, analyzed the current research about the potential uses of two-drug ART regimens. Join her now for a case-based discussion about how that new information can affect patient selection in the clinic.